Literature DB >> 6164381

Response of EMT6 multicellular tumour spheroids to hyperthermia and cytotoxic drugs.

J E Morgan, N M Bleehen.   

Abstract

The response of multicellular tumour spheroids of the EMT6 cell line to combinations of hyperthermia and Bleomycin (BLM) or Adriamycin (ADM) has been investigated. Using this model system, we have demonstrated enhanced BLM cytotoxicity at 43 degrees C and also heat-induced drug tolerance to BLM at 43 degrees C. ADM cytotoxicity was not significantly increased after 43 degrees C x 1 h but after 6 h at 42 degrees C greatly enhanced cell-killing was evident. These results are discussed in relation to our previous data for EMT6 cells growing either as monolayer cultures in vitro or as solid tumours in mice.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6164381      PMCID： PMC2010598          DOI： 10.1038/bjc.1981.59

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  14 in total

1.  Hyperthermic potentiation of cytotoxicity of Ro-07-0582 in multicell spheroids.

Authors:  R Sridhar; R Sutherland
Journal:  Int J Radiat Oncol Biol Phys       Date:  1977 May-Jun       Impact factor: 7.038

2.  A simplified method for production and growth of multicellular tumor spheroids.

Authors:  J M Yuhas; A P Li; A O Martinez; A J Ladman
Journal:  Cancer Res       Date:  1977-10       Impact factor: 12.701

3.  Hypoxic cells in an in vitro tumour model.

Authors:  R M Sutherland; R E Durand
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1973-03

4.  Kinetic response of an in vitro "tumour-model" (V 79 spheroids) to 42 degrees C hyperthermia.

Authors:  C Lücke-Huhle; H Dertinger
Journal:  Eur J Cancer       Date:  1977-01       Impact factor: 9.162

5.  Cytotoxic effects of hyperthermia and adriamycin on Chinese hamster cells.

Authors:  G M Hahn; D P Strande
Journal:  J Natl Cancer Inst       Date:  1976-11       Impact factor: 13.506

6.  Radiation response of multicell spheroids--an in vitro tumour model.

Authors:  R M Sutherland; R E Durand
Journal:  Curr Top Radiat Res Q       Date:  1976-01

7.  The influence of membrane lipid composition and procaine on hyperthermic death of cells.

Authors:  M B Yatvin
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1977-12

8.  Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation.

Authors:  G M Hahn; J Braun; I Har-Kedar
Journal:  Proc Natl Acad Sci U S A       Date:  1975-03       Impact factor: 11.205

9.  The interaction of thermal tolerance with drug cytotoxicity in vitro.

Authors:  J E Morgan; D J Honess; N M Bleehen
Journal:  Br J Cancer       Date:  1979-04       Impact factor: 7.640

10.  Interaction of hyperthermia and the hypoxic cell sensitizer Ro-07-0582 on the EMT6 mouse tumour.

Authors:  N M Bleehen; D J Honess; J E Morgan
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640
View more
  5 in total

Review 1.  Hyperthermia in cancer therapy.

Authors:  J Otte
Journal:  Eur J Pediatr       Date:  1988-08       Impact factor: 3.183

Review 2.  Multicellular spheroids. A review on cellular aggregates in cancer research.

Authors:  W Mueller-Klieser
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Effect of pH and moderate hyperthermia on doxorubicin, epirubicin and aclacinomycin A cytotoxicity for Chinese hamster ovary cells.

Authors:  L Kleeberger; E M Röttinger
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  A comparison of adriamycin and mAMSA. II. Studies with V79 and human tumour multicellular spheroids.

Authors:  C M West; I J Stratford
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Enhancement of thermal killing by polyamines V. The response of EMT6 multicellular tumour spheroids versus monolayer cells.

Authors:  E Ben-Hur; J J Shaw; N M Bleehen
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.